<unk>  is a fixed-dose combination of<unk> , a hepatitis C virus (HCV) NS5A inhibitor, and Sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor that is FDA approved for the treatment of chronic hepatitis C virus (HCV). There is a Black Box Warning for this drug as shown here.  Common adverse reactions include fatigue, headache and asthenia.
Ledipasvir / sofosbuvir
Sofosbuvir / velpatasvir
Dolutegravir / rilpivirine
Ombitasvir / paritaprevir / ritonavir / dasabuvir
Elbasvir / grazoprevir
Sofosbuvir / velpatasvir / voxilaprevir
Bictegravir / emtricitabine / tenofovir alafenamide
Glecaprevir / pibrentasvir